XBiotech Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016	2015
Market Capitalization	248	122	107	338	458	767	182	140	329	350
Market Cap Growth	-	13.95%	-68.42%	-26.11%	-40.29%	321.45%	30.32%	-57.50%	-6.09%	-
Enterprise Value	48	-78	-111	101	221	52	166	108	294	259
PE Ratio	-4.96	-4.96	-3.25	-19.43	-40.81	1.15	-8.61	-4.21	-6.23	-9.33
PS Ratio	-	-	26.64	18.39	10.41	-	-	-	-	-
PB Ratio	1.14	0.56	0.44	1.26	1.31	1.01	4.39	2.32	5.56	3.40
P/FCF Ratio	-6.38	-6.38	-6.93	5.13	-6.65	-41.51	-10.92	-3.98	-5.48	-8.01
P/OCF Ratio	-6.50	-6.50	-7.21	4.87	-7.03	-41.97	-11.00	-4.15	-7.14	-10.50
EV/Sales Ratio	-	-	-27.59	5.51	5.01	-	-	-	-	-
EV/EBITDA Ratio	3.47	3.47	3.57	-4.44	-20.83	0.07	-8.88	-3.41	-5.65	-7.04
EV/EBIT Ratio	3.22	3.22	3.29	-3.98	-17.20	0.07	-7.86	-3.25	-5.58	-6.90
EV/FCF Ratio	4.10	4.10	7.18	1.54	-3.20	-2.83	-9.97	-3.08	-4.91	-5.92
Quick Ratio	32.79	32.79	53.49	68.63	79.45	13.12	5.37	11.38	4.31	14.47
Current Ratio	33.07	33.07	54.07	71.49	81.80	11.90	5.78	11.94	4.64	14.79
Asset Turnover	0	0	0.02	0.06	0.12	0	0	0	0	0
Return on Equity (ROE)	-10.80%	-10.80%	-13.10%	-5.60%	-3.20%	288.60%	-43.10%	-46.90%	-68.50%	-37.90%
Return on Assets (ROA)	-10.50%	-10.50%	-12.70%	-5.50%	-3.20%	268.70%	-40.90%	-44.30%	-62.10%	-36.20%
Return on Capital (ROIC)	-17.14%	-17.14%	-14.35%	-9.31%	-5.24%	-3.85%	-50.71%	-56.61%	-89.33%	-36.40%
Earnings Yield	-9.88%	-20.17%	-30.79%	-5.15%	-2.45%	87.19%	-11.62%	-23.74%	-16.06%	-10.71%
FCF Yield	-7.68%	-15.68%	-14.42%	19.48%	-15.04%	-2.41%	-9.16%	-25.11%	-18.24%	-12.49%
Dividend Yield	0.00%	0.00%	0.00%	22.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Payout Ratio	0.00%	0.00%	0.00%	-431.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Buyback Yield / Dilution	0.00%	0.00%	-1.32%	2.53%	33.45%	-29.37%	-2.66%	-7.63%	-5.20%	-27.48%
Total Shareholder Return	0.00%	0.00%	-1.32%	25.03%	33.45%	-29.37%	-2.66%	-7.63%	-5.20%	-27.48%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).